RNS Number : 5875P
ValiRx PLC
11 June 2020

VALIRX PLC

("ValiRx", the "Company" or the "Group")

New shareholder communication process to be implemented

London, UK, *11 June 2020*: As part of its wider communication strategy development, ValiRx (AIM:VAL) announces the launch of a six-month trial period of a new communication process to standardise and improve shareholders' experience of communicating with the Company.

The Board recognise the importance of effective and timely communication with all stakeholders, including shareholders, investors, innovators and staff. The business and science of biomedical development can be complex and difficult to articulate in a clear and concise way through regulated channels. The Company understands and encourages the desire of shareholders to ask questions about scientific or corporate progress, and is mindful of the need to ensure all shareholders have fair and equal access to information about the Company, as required by the AIM Rules and the Market Abuse Regulations.

As part of the new strategy, a new email address will be created - Questions@Valirx.com - to allow shareholders to ask questions. Each sender will receive confirmation that their question has been received, and the questions will be compiled with answers into a periodic factsheet available to download on the Company's website. The identity of the sender will not be publicly revealed.

The questions received will be collated and summarised and answered to the fullest extent possible, with input from all relevant team members. The Company commits to the responses being clear, concise and factual. Where a question cannot be answered due to regulatory or commercial sensitivity reasons, the question will still be reported, with the reason for no answer being provided.

Dr Suzy Dilly, Chief Executive Officer, commented "Scientific progress can be challenging to report in a manner understandable by all, so it is usual for some shareholders to ask questions after an update has been notified. It is probable, that if one person asks a question that a dozen people are thinking the same, so by using the proposed Q&A system, although responses will be scheduled, we hope that all shareholders will benefit from this initiative. The six-month trial period of this approach will allow us to consider effectiveness of communication and to adjust the strategy as needed for long term use."

***** ENDS *****

For more information, please contact:

ValiRx plc	**Tel: +44 (0) 20 7073 2628**
	www.valirx.com
Suzanne Dilly	Suzanne.Dilly@valirx.com
Shareholder Questions	Questions@valirx.com
Cairn Financial Advisers LLP (Nominated Adviser)	**Tel: +44 (0) 20 7213 0880**
Liam Murray / Jo Turner / Ludovico Lazzaretti	
Peterhouse Capital Limited (Sole Broker)	**Tel: +44 (0) 20 7469 0930**
Duncan Vasey / Lucy Williams / Eran Zucker	

Notes for Editors

About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer.

The Company's business model focuses on identifying and in-licensing early stage projects, adding value through scientific development and then out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the Company reduces risk while increasing the potential for realising value.

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible.

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCGZGMVVGMGGZM